Anniina Färkkilä

Cyclic immunofluorescence of 265 high-grade serous ovarian carcinomas and random-forest feature ranking identify cancer-cell MHC-II as an adjusted predictor of longer survival marking immune-activated tumor-stroma hotspots.

The paper maps oxidative stress response in TNBC using single-cell and spatial data, identifying GCLC+ mesenchymal tumor cells linked to better patient outcomes.

The paper identifies reduced IFN-I pathway activity as a driver of chemo-refractory ovarian cancer using multi-omics analysis in a clinical trial cohort.

This study identifies BX-912 as a therapeutic agent for ovarian serous carcinoma, revealing HES1 as a target and showing synergistic effects with olaparib.

Tribus is a semi-automated tool for cell phenotyping from multiplexed imaging and proteomic data, achieving high accuracy and efficiency compared to existing methods.

This study shows chemotherapy causes myeloid-driven spatial T-cell exhaustion in ovarian cancer by altering immune cell states and interactions, suggesting new immunotherapy approaches.

The paper introduces an interactive workflow called Cyto for analyzing mass cytometry data, demonstrating its ability to capture immune cell sub-populations and tumor compositions in blood and ovarian cancer samples.